Lausanne, Switzerland, 9th April 2015 - Asceneuron SA, an emerging leader in the development of novel, oral small molecule therapeutics targeting tauopathies for Alzheimer’s and related neurodegenerative diseases, today announced that the Alzheimer’s Drug Discovery Foundation (ADDF) awarded it a USD 325,000 grant to support the development of Asceneuron’s tau modulators.
